Breast Cancer Research and Treatment

, Volume 3, Issue 1, pp 33–38 | Cite as

Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: An update

  • Arthur E. Bogden
  • Mary E. Costanza
  • Steven D. Reich
  • Thomas W. Griffin
  • William R. Cobb
Report

Summary

Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical response rates for the same drugs as reported by Carter (5). The evaluable assay rate for breast tumors was 92% as compared to 89% for gynecologic tumors. Innate drug resistance was indicated with 16 of 57 tumors (28%) which did not respond to any of the six agents tested. Differences in responsiveness of tumors to each agent in a potential three-drug combination of either CMF or CAF suggest that the effectiveness of multiagent therapy might be enhanced if the individual agents of a potential drug combination were selected on the basis of tumor sensitivity to each of the agents in a predictive assay. Although cross-resistance between L-PAM and cytoxan was demonstrated and was statistically significant, 31% of these tumors responded individually to either one or the other agent, suggesting caution in extrapolating concomitance in activity between these two alkylators.

Keywords

breast cancer drug resistance drug screening subrenal capsule assay 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bogden AE, Kelton DE, Cobb WR, Esber HJ: A rapid screening method for testing chemotherapeutic agents against human tumor xenografts.In Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research. Gustav Fischer, New York, 1978, p 321Google Scholar
  2. 2.
    Venditti JM: Preclinical drug development: rationale and methods. Semin Oncol 8:349–361, 1981PubMedGoogle Scholar
  3. 3.
    Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esber HJ: Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 41:281–293, 1979Google Scholar
  4. 4.
    Bogden AE, Cobb WR, LePage DJ, Haskell PM, Gulkin TA, Ward A, Kelton DE, Esber HJ: Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 48:10–20, 1981PubMedGoogle Scholar
  5. 5.
    Carter SK: Chemotherapy of breast cancer: current status.In JC Heuson, WH Mattheiem, and M Rozencweig (eds). Breast Cancer: Trends in Research and Treatment. Raven Press, New York, 1976, pp 193–215Google Scholar
  6. 6.
    Henderson IC, Canellos GP: Cancer of the breast: the past decade. New Engl J Med 302:78–90, 1980PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • Arthur E. Bogden
    • 1
  • Mary E. Costanza
    • 2
  • Steven D. Reich
    • 3
  • Thomas W. Griffin
    • 2
  • William R. Cobb
    • 1
  1. 1.Laboratory of Experimental OncologyEG&G Mason Research InstituteWorcesterUSA
  2. 2.Division of OncologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  3. 3.Division of Clinical Pharmacology, Department of MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations